Oragenics, Inc.

Equities

OGEN

US6840235005

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:07:07 2024-06-17 EDT			5-day change	1st Jan Change
1.65 ^USD	+0.61%		+0.24%	-70.23%

05-27	Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	CI
05-27	Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	CI

Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.

May 26, 2024

Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. These Options will be under lockup for 90 days starting from 27-FEB-2024 to 27-MAY-2024.

Details:
The executive officers and directors have agreed, for a period of three months from the date of this prospectus supplement.

Latest news about Oragenics, Inc.

Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Oragenics, Inc. Appoints William ?Frank? Peacock MD as Chief Clinical Officer	05-22	CI
Sector Update: Health Care Stocks Ease Thursday Afternoon	05-16	MT
Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise	05-16	MT
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial	05-16	CI
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Oragenics, Inc. Announces Partnership with Avance Clinical to Conduct Phase II Clinical Trial in Australia	05-07	CI
North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	03-18	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	03-05	CI
Top Midday Decliners	02-28	MT
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	02-13	MT
Oragenics, Inc. Announces Leadership Transition	02-12	CI

Chart Oragenics, Inc.

Duration

Period

More charts

Company Profile

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

Sector

Biotechnology & Medical Research

Calendar

2024-07-14 - Annual General Meeting

More about the company

	1st Jan change	Capi.
ORAGENICS, INC.	-70.23%	7.35M
VERTEX PHARMACEUTICALS INCORPORATED	+17.01%	124B
REGENERON PHARMACEUTICALS, INC.	+18.76%	112B
ARGENX SE	+3.52%	22.94B
BEIGENE, LTD.	-11.87%	17.02B
GENMAB A/S	-16.50%	16.88B
WUXI APPTEC CO., LTD.	-39.57%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.68%	13.63B
SAREPTA THERAPEUTICS, INC.	+22.88%	11.61B
INSMED INCORPORATED	+108.39%	10.31B

Bio Therapeutic Drugs

Oragenics, Inc.

Equities

OGEN

US6840235005

Biotechnology & Medical Research

Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.

Latest news about Oragenics, Inc.

Chart Oragenics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs